What is the likely cause of yellow genital discharge after a new sexual partner and what evaluation and treatment are recommended?

Yellow Discharge After New Sexual Partner

Yellow genital discharge following a new sexual partner most likely indicates a sexually transmitted infection, primarily gonorrhea, chlamydia, or trichomoniasis, and requires immediate testing with nucleic acid amplification tests (NAATs) for gonorrhea and chlamydia, plus evaluation for trichomoniasis, followed by empiric treatment if you are at high risk or cannot ensure follow-up. 1

Most Likely Causes

The differential diagnosis for yellow discharge after new sexual contact includes:

• Gonorrhea (N. gonorrhoeae) - Most common cause of purulent yellow discharge
• Chlamydia (C. trachomatis) - Frequently coexists with gonorrhea (14.3% coinfection rate) 2
• Trichomoniasis (T. vaginalis) - Presents with yellow-green, frothy discharge 3, 4
• Cervicitis/Urethritis - Often caused by the above pathogens

Yellow discharge specifically suggests mucopurulent cervicitis in women or urethritis in men, with leukorrhea (>10 WBCs per high-power field) being a sensitive indicator of cervical inflammation 1.

Diagnostic Evaluation

Testing priorities:

1. NAAT testing for gonorrhea and chlamydia - This is the preferred diagnostic method and can be performed on cervical swabs, urethral swabs, or urine samples 1

2. Trichomoniasis evaluation - NAAT is recommended by CDC for symptomatic or high-risk patients, as wet mount microscopy has only 50% sensitivity 3, 1

3. Additional testing - HIV and syphilis screening should be performed in anyone diagnosed with a new STD 5

Physical examination findings to document:

• Yellow endocervical discharge visible in the canal
• Vaginal pH (if >4.5, consider trichomoniasis or bacterial vaginosis)
• Presence of vulvar or vaginal erythema
• "Strawberry cervix" (colpitis macularis) - highly specific for trichomoniasis (OR 241) 4

Treatment Recommendations

For Women with Cervicitis

Presumptive treatment is indicated if:

• Age <25 years
• New or multiple sexual partners
• High local gonorrhea prevalence (>5%)
• Follow-up cannot be ensured 1

Recommended empiric regimen:

• Azithromycin 1 g orally single dose OR Doxycycline 100 mg orally twice daily for 7 days (for chlamydia) 1
• PLUS gonorrhea treatment if local prevalence >5%: Ceftriaxone 125 mg IM single dose 6, 7

For Men with Urethral Discharge

Recommended regimen:

• Ceftriaxone 125 mg IM single dose (for gonorrhea) 7
• PLUS Azithromycin 1 g orally single dose OR Doxycycline 100 mg orally twice daily for 7 days (for chlamydia) 5

If Trichomoniasis is Suspected or Confirmed

• Metronidazole 2 g orally single dose OR Tinidazole 2 g orally single dose 3, 5

Critical Management Points

Sexual abstinence requirements:

• Abstain from intercourse for 7 days after single-dose therapy or until completion of 7-day regimen 1
• Continue abstinence until all sex partners are treated 1

Partner management:

• All sexual contacts within 60 days before symptom onset or diagnosis must be evaluated and treated 1, 7
• If last sexual contact was >60 days ago, treat the most recent partner regardless 1
• Patient-delivered partner therapy may be considered for heterosexual partners to reduce reinfection rates 1

Follow-up strategy:

• Test-of-cure is NOT recommended at 3-4 weeks for uncomplicated cases treated with recommended regimens 1
• Retest at 3 months is strongly recommended due to high reinfection rates (especially for chlamydia in women) 1, 5
• Return sooner if symptoms persist, suggesting treatment failure or reinfection 1

Common Pitfalls to Avoid

1. Don't rely on wet mount alone for trichomoniasis - It misses 50% of cases; use NAAT when available 3, 1

2. Don't perform test-of-cure at <3 weeks - This can yield false-positive results from dead organisms or false-negatives from low organism counts 1

3. Don't forget coinfection - 30.9% of urethral discharge cases have multiple pathogens, with 14.3% having both gonorrhea and chlamydia 2

4. Don't treat empirically without risk assessment - In low-prevalence settings with reliable follow-up, awaiting test results prevents overtreatment (42% of women receive inappropriate treatment when empiric therapy is overused) 8

5. Don't neglect partner treatment - Most post-treatment infections result from reinfection by untreated partners 1